Novartis cans its Japanese brass; Crescendo closes $32.3M A round;

@FierceBiotech: Party drug turned 'miracle' cure for depression spurs hype and stubborn hope. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Celgene pays VCs $47M to up its stake in Acceleron's pipeline. More | Follow @JohnCFierce

@DamianFierce: Looking back at notes from JPM in January, Lumena said it would wait on IPO until it had more data, to drive up valuation. That was pre-Q1 boom. | Follow @DamianFierce

@EmilyMFierce: Mutations during vaccine making weakened last year's flu jab. Article via FierceVaccines | Follow @EmilyMFierce

> Novartis ($NVS) has sent some of its top Japanese execs packing as allegations of clinical trial misconduct have plagued the drugmaker. News

> Crescendo Biologics has banked another $3.3 million in the final close of its Series A financing, bringing the total to $32.3 million. Release

> Otologic Pharmaceutics raised a $4.1 million Series A to advance its lead candidate, NHPN-1010 for noise-induced hearing loss. Item

Medical Device News

@FierceMedDev: Breaking: Cardinal Health is snatching up device maker AccessClosure for $320M. Story | Follow @FierceMedDev

@MarkHFierce: Last year, my sister died, and I learned first-hand about life sciences' limits. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: ICYMI: The year in nanotech drug delivery. Report | Follow @MichaelGFierce

@EmilyWFierce: The FDA approved a hand-held, portable treatment to reverse an opioid overdose. News | Follow @EmilyWFierce

> After a successful IPO, LDR looks to raise more cash. More

> Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in. Story

Pharma News

@FiercePharma: Top-read on FiercePharmaMarketing yesterday: Eli Lilly's sales force finds CRM harmony in the cloud. Story | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. More | Follow @TracyStaton

@EricPFierce: Hikma invested $39M in NJ plant for which FDA has now closed out a warning letter from 2012. News | Follow @EricPFierce

@CarlyHFierce: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Article | Follow @CarlyHFierce

> Novartis ousts top Japanese execs amid fresh misconduct allegations. More

> More scrutiny, less pay? U.K. docs collected less cash from pharma in 2013. Story

Pharma Manufacturing News

> Apotex plant in India tagged with import ban. News

> Alexion says it will add third operation in Ireland. Story

> Merck puts big data to work to solve vaccine manufacturing concern. Article

> GSK recalls Paxil after FDA issues warning letter. News

> Hikma earns FDA closeout letter for its new Jersey plant. News

> Aurobindo gets control of 7 Actavis API plants in Europe. Brief

Vaccines News

> GlaxoSmithKline admits defeat in PhIII cancer vaccine trial. News

> Mutations during vaccine making weakened last year's flu jab. Story

> GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. Story

> CDC: Flu vaccination cuts children's risk for intensive care hospitalization. Article

> Vaccines sale figures into Baxter's breakup plans. Story

> Trump's Twitter tirade blames vaccines for autism increase. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.